RuiXin Medical Named to 2021 China Digital Healthcare Top 100 – AI in Healthcare Top 20 Ahead of IPO

From October 11 to 13, the “Tianfu Health Talk · CHS 2021 The 6th China Big Health Industry Upgrade Summit,” co-hosted by the General Practice and Health Management Committee of the Chinese Health Information and Healthcare Big Data Society and EqualOcean, was held in Chengdu. During the event, EqualOcean Intelligence and EqualOcean Health officially released the “2021 Top 100 Digital Healthcare Companies in China” list, with Ruixin Medical selected among the Top 20 AI-in-Healthcare companies on the list.

At the Digital Health Forum on the morning of the 13th, Zheng Lingxiao, CEO of RayCloud, delivered a speech on new explorations into the emerging trends and directions in AI-based medical imaging. He stated, “RayCloud’s goal is not merely to provide ‘assistant’ tools for radiologists, but to offer systematic solutions for the entire clinical workflow, encompassing a closed-loop chain that spans from screening and diagnosis to preoperative surgical planning, intraoperative analysis and guidance, and postoperative follow-up.” He emphasized that RayCloud aims to do more than just “help doctors see”and“"Seeing on behalf of doctors," and further realizing the medical philosophy and goal of "seeing what doctors cannot see."

The “2021 Top 100 Digital Health Companies in China” list, curated over several months by EqualOcean Intelligence and EqualOcean Health, aims to identify the most innovative and dynamic digital health enterprises in China, disseminate industry trends, and showcase sector insights. RayHeart Medical has accumulated extensive experience in navigating the critical pathway from concept to product for innovative medical devices, making it a highly representative player in the industry.

Over the past three years since its establishment, RuiXin Medical has built a professional team of more than 40 experts in fields such as AI deep learning, cloud computing, and biological simulation, accumulating over 300 journal publications, software copyrights, and patents. In April this year, the company’s innovative product, the “Non-invasive Coronary Hemodynamic Assessment Platform—RuiXin-FFR,” received Class III medical device registration approval from the National Medical Products Administration (NMPA), officially qualifying it for market launch. Shortly after securing hundreds of millions of RMB in Series C financing mid-year, its second product, the “RuiXin Intelligent Coronary Post-processing Platform,” also obtained NMPA certification, drawing significant attention within the industry. This achievement made RuiXin Medical the first company globally to obtain dual certifications for both morphological and functional coronary CTA products.

RayCare is committed to building and continuously refining a closed-loop ecosystem that spans large-scale screening, precise diagnostics, intraoperative guidance, and chronic disease management. Within this ecosystem, the RayCare Coronary Intelligent Post-Processing Platform enables physicians to analyze medical images more efficiently, assessing coronary stenosis and plaque morphology and characteristics from a morphological perspective, with accuracy comparable to that of invasive coronary angiography. Meanwhile, RayFFR non-invasively calculates the Fractional Flow Reserve (FFR), providing critical functional insights to guide subsequent diagnosis and treatment.

According to relevant data, Ruixin Score achieves a 92% accuracy rate in vessel-level assessment, making it the most precise CT-FFR product globally. Currently, the qualification standard for this category of products is approximately 60%; however, every 1% improvement in accuracy directly translates into a reduction in missed and misdiagnosis rates. Zheng Lingxiao emphasized, “In cardiovascular clinical diagnosis and treatment, even a mere 1% or 0.1% difference, when it truly impacts each individual and every family, becomes a matter of 100%. Therefore, the accuracy of that 1% in diagnosis is critically important.”

Large-scale experimental testing and case studies have demonstrated that the precise assessment provided by Ruixin Score can reduce unnecessary invasive coronary angiography procedures by 60%. From a health economics perspective, this significantly reduces effort and costs for all three stakeholders: For patients, it directly lowers diagnostic expenses and alleviates the suffering associated with surgical interventions. For physicians, fewer coronary angiographies mean reduced exposure to radiation, thereby lowering occupational risks while substantially conserving the energy typically allocated to stent implantation procedures. For the healthcare system, it enables more efficient allocation of medical resources and reduces consumption of disposable supplies, thereby extending the benefits of high-quality healthcare to a broader population.

Based on a combined “morphological” and “functional” assessment, the precise, non-invasive cardiovascular disease diagnosis and treatment platform provided by Rainheart Medical supports tasks such as planning for stent and bypass surgery procedures and interventional imaging guidance, thereby further empowering physicians with technology in formulating surgical plans. Currently, the surgical solution platform offered by Rainheart Medical can simulate stent deployment morphology on three-dimensional models and non-invasively calculate blood supply function before and after stent implantation, helping physicians pre-test the outcomes of multiple surgical approaches to develop more comprehensive and holistic surgical plans.

During the process of innovative translation and commercialization, Ruixin has achieved successful product implementation, becoming the first company globally to obtain dual certifications for both morphological and functional coronary CTA products. This achievement is underpinned by the team’s profound accumulation in technological research and development. Taking AI deep learning as an example, Ruixin Fraction’s secondary vascular segmentation technology leverages deep neural networks to achieve pixel-level vessel segmentation within three minutes, with precision exceeding image resolution. Meanwhile, the Ruixin Coronary Intelligent Post-Processing Platform, built on multiple AI algorithms, fully automates the calculation of stenosis severity and the qualitative assessment of plaque type and characteristics. The platform achieves a 99% accuracy rate in automatic vessel annotation and completes the entire workflow—from complex analytical diagnosis to report generation—within three to five minutes.

Research in the field of fluid dynamics also provides a strong guarantee for the technical accuracy of RayHeart Medical. By using Computational Fluid Dynamics (CFD), RayHeart Fraction can divide the three-dimensional coronary artery model into millions of units, utilizing the computing power of supercomputers to calculate the flow velocity and pressure on each unit. As a result, the calculated value of fractional flow reserve is more accurate and stable.

Ruixin Medical has also established key technological barriers in the fields of cloud computing, big data, and computational mechanics simulation.

In the past, AI-based imaging primarily served to enhance the efficiency of radiology departments alone, confined to the “workstation software” model. Raytelligence Medical, however, is committed to unlocking the potential of AI in healthcare by providing clinical solutions that address pain points across the entire disease journey. It establishes a closed-loop system spanning screening, diagnosis, treatment, interventional procedures, and prognostic follow-up, creating a precise, non-invasive diagnostic and therapeutic platform that integrates morphological and functional assessments. This approach truly realizes the vision of “ensuring every blood vessel receives the earliest possible diagnosis and the most precise treatment.”